Table 1.
Demographic and Clinical Characteristics of the Cohort
| Cohort Characteristics | Men | Women |
|---|---|---|
| Age, y, median (IQR) | 43 (33–48) | 41 (35–48) |
| CD4 nadir cells/μL, median (IQR) | 270 (131–442) | 214 (111–317) |
| CD4 at sampling cells/μL, median (IQR) | 646 (544–825) | 677 (530–861) |
| Duration of infection, y, median (IQR) | 7 (4.0–11.5) | 8 (4.8–14.3) |
| Duration of viral suppression, y, median (IQR) | 3.3 (2.1–6.7) | 2.8 (1.8–4.3) |
| Max pretreatment VL, median (IQR) | 4.74 (4.4–5.4) | 4.61 (3.8–5.2) |
| Controller (majority of pretreatment VL <10000) | 6 (23) | 9 (35) |
| CMV positive | 26 (100) | 21 (81) |
| Active HCV infection | 2 (7.7) | 1 (3.8) |
| IDU | 3 (12) | 5 (19) |
| Timing of ART initiationa | ||
| Early, continuous | 1 (4) | 1 (4) |
| Late | 20 (77) | 20 (77) |
| Early and interrupted or unknown | 5 (19) | 5 (19) |
| ART regimen | ||
| PI | 3 (12) | 9 (35) |
| NNRTI | 12 (46) | 11 (42) |
| INSTI | 9 (35) | 6 (23) |
| PI/INSTI | 1 (4) | 0 |
| NNRTI/INSTI | 1 (4) | 0 |
| Race/ethnicity | ||
| White | 9 (35) | 8 (31) |
| Black | 7 (27) | 6 (23) |
| Hispanic | 4 (15) | 4 (15) |
| Asian | 2 (8) | 3 (12) |
| Native American | 1 (4) | 0 |
| Mixed/multiracial/other | 3 (11) | 5 (19) |
| History of sex with male partner(s) | 24 (92) | 26 (100) |
Data are presented as No. (%) unless otherwise indicated. Observations were available for all subjects (26 women and 26 men) with the exception of maximum pretreatment VL; this value was missing in 5 observations, all from the female subjects.
Abbreviations: ART, antiretroviral therapy; CMV, cytomegalovirus; HCV, hepatitis C virus; IDU, injection drug use; IQR, interquartile range; INSTI, integrase strand transfer inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; VL, viral load.
aDefinitions for timing of ART initiation: early is continuous is therapy initiated ≤6 months from estimated date of infection with continuous suppression; late is therapy initiated >6 months after estimated date of infection; early, interrupted, or unknown includes participants with unknown timing of therapy initiation and those who started within 6 months of infection but had interruptions with viral rebound after that point.